DIRS.INFO The most relevant business & tech news

[1/2] A UnitedHealth Group health insurance card is seen in a wallet in this picture illustration October 14, 2019. REUTERS/Lucy Nicholson/Illustration/File Photo Acquire Licensing RightsOct 13 (Reuters) - UnitedHealth (UNH.N) reported a third-quarter profit on Friday ahead of analysts' estimates, helped by a lower-than-feared rise in medical costs at the company's health insurance unit. UnitedHealth's profit beat and slight raise in annual forecast set the stage for other insurers in the industry that suffered a nearly $60-billion wipeout in market value in June, on fears of a spike in medical costs. UnitedHealth said in July it expects quarterly medical costs to be "a little bit lower" sequentially. In the third quarter, the company's medical loss ratio, the percentage of spend on claims compared to premiums collected, was 82.3%, versus 83.2% in the second quarter.

Persons: Lucy Nicholson, Stephens, Scott Fidel, UnitedHealth, Mariam Sunny, Bhanvi, Shounak Dasgupta Organizations: REUTERS, Humana, Thomson Locations: COVID, Bengaluru

☆ UnitedHealth beats quarterly profit estimates on easing medical costs
▼ + stars: | 2023-10-13 | by ( ) www.reuters.com time to read: +1 min

REUTERS/Lucy Nicholson/Illustration/File Photo Acquire Licensing RightsOct 13 (Reuters) - UnitedHealth (UNH.N) reported a third-quarter profit on Friday that beat analysts' estimates, helped by lower-than-expected medical costs for the healthcare conglomerate. UnitedHealth said in July it expects medical costs for the third quarter to be "a little bit lower" compared with the second quarter. The company's medical loss ratio for the quarter, the percentage of spend on claims compared to premiums collected, was 82.3%, compared with analysts' estimates of 82.82%, according to LSEG data. UnitedHealth reported an adjusted profit of $6.56 per share for the third quarter, compared with estimates of $6.32. The company now expects an adjusted profit between $24.85 and $25.00 per share, compared with its previous outlook of $24.70 to $25.00.

Persons: Lucy Nicholson, UnitedHealth, Mariam Sunny, Bhanvi, Shounak Dasgupta Organizations: REUTERS, Thomson Locations: Bengaluru

☆ Strike by 75,000 Kaiser Permanente healthcare workers enters third day
▼ + stars: | 2023-10-06 | by ( Steve Gorman | ) www.reuters.com time to read: +6 min

Healthcare workers strike in front of Kaiser Permanente Los Angeles Medical Center, as more than 75,000 Kaiser Permanente healthcare workers go on strike from October 4 to 7 across the United States, in Los Angeles, California, U.S. October 4, 2023. Kaiser has said its hospitals and emergency departments have remained open despite the walkout, staffed by doctors, managers and "contingency workers." In any case, Lucas said the striking workers will all return to their jobs by 6 a.m. on Saturday, 72 hours after the strike began, because healthcare workers by law must give advance notice of 10 days of any intent to go on strike. However, the union on Friday warned of another strike if "Kaiser executives continue to commit unfair labor practices and bargain in bad faith." The Kaiser strike has idled more than 75,000 employees, union officials said.

Persons: Kaiser, Julie Su, Caroline Lucas, Lucas, Steve Gorman, Ahmed Aboulenein, Bhanvi, Bill Berkrot, Robert Birsel, Anil D'Silva Organizations: Kaiser Permanente Los Angeles Medical Center, Permanente, REUTERS, Kaiser Permanente, District of Columbia, Labor, Coalition, Kaiser Permanente Unions, Kaiser, Union, Unions, U.S . Bureau of Labor Statistics, Washington D.C, Thomson Locations: United States, Los Angeles , California, U.S, Kaiser, California , Oregon, Washington, , Colorado, Virginia, California, Las Vegas, California , Colorado , Oregon, Hawaii , Georgia, Los Angeles, Bengaluru

[1/7] Healthcare workers strike in front of Kaiser Permanente Los Angeles Medical Center, as more than 75,000 Kaiser Permanente healthcare workers go on strike from October 4 to 7 across the United States, in Los Angeles, California, U.S. October 4, 2023. Kaiser said its hospitals and emergency departments remained open, staffed by doctors, managers and "contingency workers." They are represented by the SEIU United Healthcare Workers West. The Kaiser labor coalition, made up of eight unions representing medical professionals and support staff, insists the company needs to hire 10,000 new healthcare workers to fill current vacancies. Kaiser nationwide employs 68,000 nurses and 213,000 technicians, clerical workers, and administrative staff, alongside its 24,000 doctors.

Persons: Kaiser, Christina Andersen, Michael LeRoy, Ahmed Aboulenein, Bhanvi Satija, Bill Berkrot Organizations: Healthcare, Kaiser Permanente Los Angeles Medical Center, Permanente, REUTERS, Rights, Kaiser Permanente, U.S . Bureau of Labor Statistics, District Columbia, Kaiser, Labor, Tenet Healthcare, SEIU United Healthcare Workers, SEIU, University of Illinois, D.C, Thomson Locations: United States, Los Angeles , California, U.S, Kaiser, California , Oregon, Washington , Colorado, Virginia, Claremont , California, California, Los Angeles, Las Vegas, University of Illinois Urbana, Champaign, Washington, California , Colorado , Oregon

[1/7] Healthcare workers strike in front of Kaiser Permanente Los Angeles Medical Center, as more than 75,000 Kaiser Permanente healthcare workers go on strike from October 4 to 7 across the United States, in Los Angeles, California, U.S. October 4, 2023. "After six months of bargaining with the Coalition of Kaiser Permanente Unions, including a marathon effort that went through last night and into today, our bargaining sessions unfortunately ended without a settlement," Kaiser said. They are represented by the SEIU United Healthcare Workers West. The Kaiser labor coalition, made up of eight unions representing medical professionals and support staff, insists the company needs to hire 10,000 new healthcare workers to fill current vacancies. Kaiser nationwide employs 68,000 nurses and 213,000 technicians, clerical workers, and administrative staff, alongside its 24,000 doctors.

Persons: Kaiser, Christina Andersen, Michael LeRoy, Ahmed Aboulenein, Bhanvi Satija, Bill Berkrot, Navaratnam 私 Organizations: Healthcare, Kaiser Permanente Los Angeles Medical Center, Permanente, REUTERS, Rights, Kaiser Permanente, Reuters, Coalition, Kaiser Permanente Unions, U.S . Bureau of Labor Statistics, District Columbia, Kaiser, Labor, Tenet Healthcare, SEIU United Healthcare Workers, SEIU, University of Illinois, D.C Locations: United States, Los Angeles , California, U.S, California , Oregon, Washington , Colorado, Virginia, Claremont , California, California, Los Angeles, Las Vegas, University of Illinois Urbana, Champaign, Washington, California , Colorado , Oregon

Healthcare workers strike in front of Kaiser Permanente Los Angeles Medical Center, as more than 75,000 Kaiser Permanente healthcare workers go on strike from October 4 to 7 across the United States, in Los Angeles, California, U.S. October 4, 2023. WHAT ARE KAISER WORKERS' DEMANDS AND WHAT IS THE COMPANY OFFERING? Some of the key demands by the workers include higher pay to keep up with the cost of living, a $25-per-hour minimum wage for all healthcare workers, and a reformed bonus structure. The union insists Kaiser needs to hire 10,000 new healthcare workers to fill current vacancies, as well as "fix broken hiring processes" that are preventing full staffing. The unions are asking Kaiser Permanente to make massive investment in the education and training of future healthcare workers, and for a diminished role for vendors and third-party contractors that the healthcare network relies on.

Persons: Julie Su, Kaiser, Kaiser Permanente, John August, Russ Richmond, Leroy Leo, Bhanvi, Ahmed Aboulenein, Steve Gorman, Shinjini Ganguli, Diane Craft Organizations: Kaiser Permanente Los Angeles Medical Center, Permanente, REUTERS, Kaiser Permanente, Labor, AMN Healthcare, District of Columbia, Cornell's School of Industrial and Labor Relations, Tenet Healthcare, Satellite Healthcare, Fresenius, Thomson Locations: United States, Los Angeles , California, U.S, Kaiser, California, Bengaluru, Washington, Los Angeles

☆ Lilly eyes targeted cancer therapies with $1.4 billion Point Biopharma deal
▼ + stars: | 2023-10-03 | by ( Bhanvi Satija | Leroy | ) www.reuters.com time to read: +2 min

(Reuters) -Eli Lilly and Co will buy Point Biopharma Global for $1.4 billion, the companies said on Tuesday, gaining access to experimental therapies that enable precise targeting of cancer. Lilly has offered $12.50 per Point Biopharma share held, representing a premium of about 87% to the stock’s last close. Shares of Indiana-based Point Biopharma soared 85%, while Lilly’s stock was down about 3%. Point Biopharma has licensed both its late-stage experimental therapies to Lantheus Holdings since 2022. A Lantheus spokesperson said the company’s commercial rights remain intact and its collaboration with Point Biopharma is progressing in line with expectations.

Persons: Eli Lilly, Mike Segar, Lilly, ”, William Blair, Andy Hsieh Organizations: Reuters, Company, REUTERS, Dice Therapeutics, Novartis, Lantheus Holdings Locations: Branchburg , New Jersey, Indiana, Biopharma’s Indianapolis, PNT2002, U.S

REUTERS/Dado Ruvic/Illustration/File photo Acquire Licensing RightsOct 3 (Reuters) - The U.S. Food and Drug Administration staff reviewers said on Tuesday Amgen's (AMGN.O) late-stage study might not be sufficient to confirm the effectiveness for its lung cancer drug, as the firm pursues a traditional nod for the treatment. Amgen's drug was granted accelerated approval by the U.S. FDA in 2021 for advanced lung cancer patients with KRAS mutations whose disease has worsened after treatment with chemotherapy or other medicines. The U.S. health regulator grants the so-called accelerated approval based on data that show therapies are likely to work, and requires confirmatory trials later to give them traditional approval. Data from the study showed Lumakras reduced the risk of disease progression in patients with advanced lung cancer by 34%, compared with chemotherapy in a clinical trial. The agency is expected to make a decision on traditional approval for the drug by Dec. 24.

Persons: Dado Ruvic, Amgen's, William Blair, Matt Phipps, Lumakras, Bhanvi Satija, Shounak Dasgupta, Sherry Jacob, Phillips Organizations: REUTERS, U.S . Food, Drug Administration, U.S, FDA, Thomson Locations: U.S, Bengaluru

☆ Structure Therapeutics surges on promising early stage obesity drug data
▼ + stars: | 2023-09-29 | by ( ) www.reuters.com time to read: +1 min

Sept 29 (Reuters) - Shares of Structure Therapeutics (GPCR.O) soared 60% on Friday after the drug developer's oral obesity treatment succeeded in a small early-stage study. The drug, GSBR-1290, belongs to the same class of treatments as Novo Nordisk's (NOVOb.CO) blockbuster weight-loss drug Wegovy and Eli Lilly's (LLY.N) diabetes drug Mounjaro. Structure has said it is focused on developing oral obesity drugs that are simpler to manufacture than the current injectables. Structure "delivered better-than-expected efficacy and tolerability" for its oral drug, said Leerink Partners Research analyst David Risinger, adding that the early data was exceptional. Structure said it plans to test GSBR-1290 in two mid-stage studies as a treatment for type 2 diabetes and obesity.

Persons: Eli Lilly's, David Risinger, Bhanvi Organizations: Therapeutics, Leerink Partners, Nasdaq, Thomson Locations: California, Bengaluru

Sept 26 (Reuters) - Shares of Immunovant (IMVT.O) surged nearly 80% on Tuesday, after early-stage data from its experimental antibody treatment exceeded analysts' expectations. Immunovant is developing its antibody drug, IMVT-1402, as an under-the-skin injection to potentially treat autoimmune diseases. Immunovant's experimental drug reduced the levels of IgG, or immunoglobulin antibodies, that cause inflammation and disease in healthy adults. Shares of Roivant Sciences (ROIV.O), Immunovant's largest shareholder with a 56.5% stake, according to LSEG data, also rose 17.5% to $12. The positive data from IMVT-1402 could give Roivant another "potentially blockbuster" candidate to transact, after its experimental treatment for bowel disease, Jefferies analyst Dennis Ding said.

Persons: J.P, Morgan, Brian Cheng, drugmakers Johnson, Johnson, Hytrulo, Immunovant, transact, Jefferies, Dennis Ding, Bhanvi, Krishna Chandra Organizations: UCB, Roivant Sciences, Thomson Locations: United States, York, IMVT, Bengaluru

☆ Explainer: What you need to know about RSV and the new vaccines
▼ + stars: | 2023-09-22 | by ( Michael Erman | ) www.reuters.com time to read: +4 min

That Pfizer (PFE.N) shot and one developed by GSK (GSK.L) in May became the first two RSV vaccines to win U.S. approval, for use in people aged 60 and over to prevent severe illness. Still, infants and older adults have a higher risk of developing severe RSV. RSV leads to 58,000 to 80,000 hospitalizations among children under age 5, and 60,000 to 160,000 hospitalizations among adults age 65 and older each year, according to the CDC. Early data suggests that the RSV shots are protective for at least two years, but it is not yet clear how often older adults will need to be revaccinated. Can I get the RSV shot alongside my COVID and flu shots?

Persons: Pfizer's, Synagis, it's, Jeffrey Duchin, you've, Michael Erman, Bhanvi, Caroline Humer, Bill Berkrot Organizations: . Centers for Disease Control, Prevention, Pfizer, GSK, CDC, FDA, Sanofi, AstraZeneca, Infectious Diseases Society of America, CVS, Humana, Thomson Locations: U.S, Aetna, New York, Bengaluru Edtiting

☆ Europe to decide on Novavax's COVID vaccine in October
▼ + stars: | 2023-09-21 | by ( ) www.reuters.com time to read: +1 min

Four vials with the "Nuvaxovid" COVID-19 vaccine from Novavax are pictured in Saabruecken, Germany, February 26, 2022. REUTERS/Frank Simon/File photo Acquire Licensing RightsSept 21 (Reuters) - The European Medicines Agency (EMA) expects to decide on the use of Novavax's (NVAX.O) updated COVID-19 vaccine in October, its director Emer Cooke said on Thursday. The agency had started the evaluation process for the protein-based shot on Aug. 24, Cooke said at a press conference. EU regulators recently gave the green light for an updated COVID-19 vaccine from Pfizer (PFE.N) and its German partner BioNTech (22UAy.DE), which targets the XBB.1.5 variant of Omicron. Moderna's (MRNA.O) updated shot is also on track to win approval.

Persons: Frank Simon, Emer Cooke, Cooke, BioNTech, Novavax, Bhanvi, Michael Erman, Saumyadeb Chakrabarty Organizations: REUTERS, European Medicines Agency, Pfizer, U.S . Food, Drug Administration, FDA, Moderna, Thomson Locations: Saabruecken, Germany, United States, Bengaluru, New York

☆ Moderna flu shot succeeds in late-stage study
▼ + stars: | 2023-09-13 | by ( Patrick Wingrove | ) www.reuters.com time to read: +4 min

The effectiveness of Moderna's flu vaccine was demonstrated across all age groups, including older people, and was found to be safe and tolerable, according to the company. Moderna also said it had found that its shot was equal or superior to Sanofi's high-dose flu vaccine in a separate early head-to-head study. Following the U.S. Food and Drug Administration's authorization on Monday, Moderna said it would start shipping COVID vaccine doses across the United States. "The vaccine's manufacturing runs from June to October and we are already producing it. All the purchase orders are being fulfilled," a Rovi spokesperson said, referring to the COVID vaccine.

Persons: Dado Ruvic, Moderna, Jefferies, Michael Yee, Stephen Hoge, Hoge, we've, We've, COVID, Spain's, Patrick Wingrove, Will Dunham, Mark Porter Organizations: REUTERS, Moderna, U.S . Centers for Disease Control, U.S . Food, Sanofi, Thomson Locations: United States, Moderna, Massachusetts, Britain, Canada, Japan, China, New York, Bengaluru

☆ Moderna to scale down manufacturing of COVID vaccine
▼ + stars: | 2023-09-13 | by ( Patrick Wingrove | ) www.reuters.com time to read: +3 min

The downsizing, Hoge added, will help Moderna adjust to the endemic phase of the disease, which had led to falling demand for COVID vaccines as payers scale back orders for the shots. Moderna predicted in August that U.S. demand for the vaccine would reach 50 to 100 million doses in the fall season. Following the U.S. Food and Drug Administration's authorization on Monday, Moderna said it would start shipping COVID vaccine doses across the United States. The effectiveness of Moderna's flu vaccine was demonstrated across all age groups, including older patients, and was found to be safe and tolerable, according to the company. Moderna also said it had found that its shot was equal or superior to Sanofi's high-dose flu vaccine in a separate early head-to-head study.

Persons: Stephen Hoge, Hoge, Moderna, we've, We've, COVID, Patrick Wingrove, Bhanvi, Will Dunham Organizations: Moderna, Sanofi, Wednesday, U.S . Centers for Disease Control, U.S . Food, Thomson Locations: Moderna, Massachusetts, United States, Britain, Canada, Japan, China, New York, Bengaluru

☆ COVID vaccine manufacturers set list price between $120-$130 per dose
▼ + stars: | 2023-09-12 | by ( ) www.reuters.com time to read: +1 min

A patient receives their coronavirus disease (COVID-19) vaccine booster during a Pfizer-BioNTech vaccination clinic in Southfield, Michigan, U.S., September 29, 2021. REUTERS/Emily Elconin/File photo Acquire Licensing RightsCompanies BioNTech SE FollowModerna Inc FollowNovavax Inc Follow Show more companiesSept 12 (Reuters) - U.S. COVID vaccine manufacturers set list prices for their shots between $120 and $130 per dose, company executives said at an advisory panel meeting of U.S. Centers for Disease Control and Prevention on Tuesday. Pfizer (PFE.N) and German partner BioNTech (22UAy.DE) set the list price at $120 per dose, while Moderna (MRNA.O) said the list price for its shot is $129 per dose, for their respective COVID vaccines. Novavax (NVAX.O) said the list price for its COVID vaccine was $130 per dose. Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

Persons: Emily Elconin, BioNTech, Bhanvi Satija, Sriparna Roy, Shounak Dasgupta Organizations: Pfizer, REUTERS, U.S . Centers for Disease Control, Moderna, Thomson Locations: Southfield , Michigan, U.S, Bengaluru

The updated shots are part of a push by public health officials to align the next COVID vaccines more closely with the actual circulating variant of the virus, similar to the way annual flu shots are designed. The U.S. Food and Drug Administration (FDA) on Monday authorized updated COVID vaccines made by Pfizer (PFE.N) and its German partner BioNTech SE (22UAy.DE) as well as by Moderna (MRNA.O). CDC Director Mandy Cohen is expected to approve the recommendations issued by the advisers, allowing Americans to get the updated vaccines. The first COVID vaccines in 2020 were monovalent, or single-target vaccines, aimed at the original strain of the virus. They were followed by bivalent COVID vaccine booster shots that targeted both the original and the Omicron strains.

Persons: Emily Elconin, BioNTech, Caitlin Rivers, Mandy Cohen, Rivers, bivalent, Daniel Kuritzkes, Eris, Kuritzkes, Novavax, Bhanvi, Julie Steenhuysen, Will Dunham, Caroline Humer Organizations: REUTERS, U.S . Centers for Disease Control, Prevention, U.S . Food, Drug Administration, Pfizer, Moderna, FDA, Johns Hopkins Center for Health Security, CDC, Omicron, Brigham, Women's Hospital, Vaccine, EG, Thomson Locations: Waterford , Michigan, U.S, United States, Baltimore, Europe, Asia, Boston, Moderna, Bengaluru, Chicago

Sept 7 (Reuters) - Insulet Corp's (PODD.O) shares hit an over three-year low on Thursday on concerns that strong demand for a new class of diabetes drugs that also aid in weight loss could hit sales of its insulin pumps. CEO James Hollingshead said at the Wells Fargo Healthcare Conference that GLP-1 drugs, which are used to treat type-2 diabetes and obesity, could delay the onset of insulin dependency in diabetes patients. GLP-1s are highly effective weight-loss drugs that some analysts predict could become a $100 billion market by 2030. Shares of Massachusetts-based Insulet fell about 12% to $170.87 and were on track to wipe off about $1.6 billion from the company's market capitalization if losses hold. Insulet manufactures and sells insulin delivery devices, which eliminate the need for multiple daily injections for people with insulin-dependent diabetes.

Persons: James Hollingshead, Novo, Trang Ly, Bhanvi, Anil D'Silva Organizations: Wells, Healthcare Conference, New England, of Medicine, Massachusetts, Thomson Locations: Bengaluru

☆ Illumina taps Agilent's Jacob Thaysen as CEO
▼ + stars: | 2023-09-05 | by ( Bhanvi Satija | ) www.reuters.com time to read: +2 min

FILE PHOTO: A sign at the front entrance to the global headquarters of Illumina is pictured in San Diego, California, U.S., November 28, 2022. REUTERS/Mike Blake/File Photo(Reuters) -Illumina on Tuesday named Agilent Technologies’ Jacob Thaysen as its CEO, months after the former head of the U.S. genetic testing company resigned following a proxy fight with billionaire Carl Icahn. The company said Thaysen, 48, who has been part of the analytical instruments division leadership at Agilent since 2018, would take the helm effective Sept. 25. Thaysen “checks all the boxes” required for the CEO role with his expertise in medical tools industry and understanding of Illumina’s customer base, said Evercore analyst Vijay Kumar. Thaysen will replace interim CEO Charles Dadswell, who will resume as senior vice president and general counsel at Illumina.

Persons: Mike Blake, Jacob Thaysen, Carl Icahn, Illumina, Icahn, Thaysen, Vijay Kumar, John Thompson, Andrew Teno, Francis deSouza, deSouza, Charles Dadswell, Patrick Donnelly Organizations: REUTERS, Illumina, Citi Locations: San Diego , California, U.S, Agilent, Illumina, China

☆ Factbox: What are global companies saying about China's economy?
▼ + stars: | 2023-08-29 | by ( ) www.reuters.com time to read: +1 min

People cross a street near office towers in the Lujiazui financial district in Shanghai, China, February 28, 2023. REUTERS/Aly Song/File Photo Acquire Licensing RightsAug 29 (Reuters) - United States Commerce Secretary Gina Raimondo has said U.S. companies have raised concerns that China has become "uninvestible", pointing to fines, raids and other actions that have made it too risky to do business in the world's second-largest economy. Major global firms ranging from banks to chipmakers are taking a largely cautious stance on their China business amid a frail recovery of the country's economy from a pandemic slowdown. Following are comments from some of the top firms on their China business during the latest reporting season:Compiled by Savyata Mishra, Arunima Kumar, Niket Nishant, Granth Vanaik, Aditya Soni and Bhanvi Satija; Edited by Shinjini Ganguli and Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

Persons: Aly, Gina Raimondo, Savyata Mishra, Arunima Kumar, Niket Nishant, Granth Vanaik, Aditya Soni, Bhanvi, Shinjini Ganguli, Shounak Organizations: REUTERS, United States, Thomson Locations: Shanghai, China, U.S

REUTERS/Brendan McDermid/File Photo/File Photo Acquire Licensing RightsAug 25 (Reuters) - AstraZeneca (AZN.L) said on Friday it has sued the U.S. government to block parts of a program that gives the Medicare health insurance plan the power to negotiate lower drug prices. The program faces at least seven other court challenges, including from leading industry group PhRMA and drugmakers Johnson & Johnson (JNJ.N), Merck & Co (MRK.N), Bristol Myers Squibb (BMY.N) and privately-held Boehringer Ingelheim. The drug price negotiation program is part of President Joe Biden's signature Inflation Reduction Act (IRA). ‍AstraZeneca said the program would deter continued development of treatments such as its cancer drug Lynparza and rare blood disorder drug Soliris, which carry orphan drug status for multiple conditions. An HHS spokesperson said in a statement that the agency "will vigorously defend the President's drug price negotiation law, which is already helping to lower healthcare costs for seniors and people with disabilities."

Persons: Brendan McDermid, drugmakers Johnson, Johnson, Joe Biden's, AstraZeneca, Bhanvi, Dhanya Ann Thoppil, Shilpi Majumdar Organizations: AstraZeneca, New York Stock Exchange, REUTERS, U.S, Merck & Co, Bristol Myers Squibb, U.S . Department of Health, Human Services, Thomson Locations: British, Delaware, United States, U.S, Bengaluru

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. The drug price negotiation program is part of President Joe Biden's signature Inflation Reduction Act (IRA). The program faces several other court challenges, including from leading industry groups and other drug companies. ‍AstraZeneca said it was filing a legal challenge in a bid to "protect timely access to medicines for orphan indications" in the United States. Reporting by Bhanvi Satija in Bengaluru; Editing by Dhanya Ann Thoppil and Shilpi MajumdarOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Joe Biden's, AstraZeneca, Bhanvi, Dhanya Ann Thoppil, Shilpi Majumdar Organizations: AstraZeneca, New York Stock Exchange, REUTERS, drugmaker AstraZeneca, Thomson Locations: United States, Bengaluru

Medtronic Plc logo is seen displayed in this illustration taken, April 10, 2023. Medtronic, which makes pacemakers, catheters and other tools used in heart and gastrointestinal surgeries, joins rivals, including Abbott Laboratories (ABT.N), Stryker (SYK.N) and Boston Scientific (BSX.N), on benefiting from a rise in non-urgent surgeries. CEO Geoff Martha said trends pointed to a recovery in surgical volumes as some procedures returned to stronger than pre-pandemic levels. Whereas, revenue from its medical surgical unit rose 5.5% to $2.04 billion. Medtronic also said that it was expecting to split its patient monitoring and respiratory interventions businesses in the first half of fiscal 2025.

Persons: Dado Ruvic, Stryker, Geoff Martha, It's, Martha, Edward Jones, John Boylan, Medtronic, Bhanvi Satija, Christy Santhosh, Shweta Agarwal Organizations: REUTERS, Abbott, Abbott Laboratories, Boston, Thomson Locations: Dublin, Bengaluru

☆ Medtronic raises forecast as demand for heart devices powers upbeat results
▼ + stars: | 2023-08-22 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsAug 22 (Reuters) - Medtronic (MDT.N) on Tuesday raised its annual profit forecast, after beating first-quarter estimates on higher demand for its medical devices used in heart and gastrointestinal surgeries. A recovery in non-urgent procedures and easing staffing shortages following a decline in COVID-19 cases has boosted the demand for medical devices. Sales at Medtronic's heart devices unit, its biggest revenue driver, increased 5.5% to $2.85 billion for the first quarter, above analysts' estimates of $2.78 billion. Revenue for the quarter rose 4.5% to $7.70 billion, topping analysts' average estimate of $7.57 billion. Its adjusted profit of $1.20 per share for the quarter ended July 28 beat estimates of $1.11 per share.

Persons: Dado Ruvic, Medtronic, Stryker, Bhanvi Satija, Christy Santhosh, Shweta Agarwal Organizations: REUTERS, Abbott Laboratories, Boston, Revenue, Thomson Locations: COVID, Dublin, Bengaluru

☆ J&J to hold 9.5% stake in Kenvue after share exchange offer
▼ + stars: | 2023-08-21 | by ( ) www.reuters.com time to read: 1 min

The company logo for Kenvue Inc. Johnson & Johnson's consumer-health business, is displayed on during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsAug 21 (Reuters) - Johnson & Johnson (JNJ.N) said on Monday it was expecting to retain a stake of about 9.5% in its newly separated consumer health unit, Kenvue (KVUE.N), after completing a share exchange offer. Shares of the consumer health company rose 1.4% in premarket trading. ‍J&J launched the exchange offer last month under which its stockholders could opt for shares of the former consumer health unit related to the spinoff. Reporting by Bhanvi Satija and Mariam Sunny in Bengaluru; Editing by Anil D'SilvaOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Johnson, ‍, J, Bhanvi Satija, Mariam Sunny, Anil D'Silva Organizations: Kenvue Inc, Johnson, New York Stock Exchange, REUTERS, Thomson Locations: New York City, U.S, Bengaluru

Aug 21 (Reuters) - The U.S. Food and Drug Administration on Monday approved Pfizer's (PFE.N) respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies. An FDA panel of outside experts backed the safety and effectiveness of Pfizer's RSV vaccine for women in their second and third trimesters earlier in May. RSV is a common respiratory virus that usually causes mild, cold-like symptoms but can also lead to serious illness and hospitalization. Infants are at greatest risk for severe illness from RSV. An estimated 58,000 to 80,000 children below the age of five years are hospitalized every year due to RSV infection in the U.S., according to government data.

Persons: Pfizer, Mariam Sunny, Bhanvi, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: U.S . Food, Drug Administration, FDA, Pfizer, U.S . Centers for Disease Control, Sanofi, AstraZeneca, GSK, Thomson Locations: U.S, United States, Bengaluru, New York

Search resuls for: "Bhanvi Satija"

25 mentions found